OUR DEVELOPMENT PORTFOLIO

 

latest update 21 January 2019

Cardiovascular diseases



Diabetes



Cancer



Immune-
Inflammatory diseases



Neuropsychiatric diseases


Phase 1

Ischemic stroke

TAFIa inhibitor

Chronic heart failure

Anti Mir92a

Cancer

Mcl1 inhibitor

Cancer

Bcl2 inhibitor

Cancer

UCART 19

Cancer

Flotetuzumab (CD123xCD3)

Cancer

MPS1 inhibitor

Colorectal cancer, 2nd line

Trifluridine/Tipiracil

Lung cancer, 2nd line

Liposomal Irinotecan

Cancer, 1st line

mPaCa / Liposomal Irinotecan

Phase 2

Venous leg ulcers
Osteoarthritis

ADAMTS-5 inhibitor

Post stroke

GABA A α5 antagonist

Phase 3

Chronic heart failure

Omecamtiv mecarbil

Type 2 diabetes

Exenatide implant

Lymphoma, 2nd line

Pixantrone

Colorectal cancer, 1st line

Trifluridine/Tipiracil

Autism

Bumetanide